|
活動內容 |
Cardiovascular disease (CVD) is an often overlooked threat for breast cancer survivors, causing 35% of non-breast cancer mortality for survivors over 50 years of age, making it the most significant non-cancer cause of death. The interplay between breast cancer and CVD is often complex and characterized by shared risk factors, including alcohol and tobacco use, obesity, hormone replacement, and advanced age. Additionally, the cardiovascular toxicities induced by treatment modalities, such as anthracycline, trastuzumab, and radiotherapy, also contribute to this coexistence. Patient education on optimal lifestyle behaviors is the first step in reducing cardiovascular events. Comprehensive cardiovascular risk assessment and functional evaluation before, during, and after treatment with cardiotoxic agents is also mandatory. Lastly, management of co-existing cardiovascular risk factors, with early identification and intervention of treatment-induced cardiac dysfunction, is crucial to mitigating CVD-related mortality and morbidity in this vulnerable population. |